Transforming growth factor beta-derived peptide-specific CD4+ T cell (TGF-β-specific CD4+ T cell)

Transforming growth factor beta (TGF-β)-derived peptide-specific CD4+ T cells are a specialized subset of helper T lymphocytes that recognize epitopes derived from the TGF-β protein when presented on MHC class II molecules. TGF-β is a critical immunosuppressive cytokine that is frequently upregulated in the tumor microenvironment, where it inhibits the activity of effector T cells and promotes the expansion of regulatory T cells (Martinenaite et al., 2020, Nature Communications). These specific CD4+ T cells are the primary focus of novel cancer vaccines, such as IO112, which are designed to stimulate an endogenous immune response against TGF-β-producing cells (IO Biotech, 2024). By activating these T cells, the therapy aims to convert the immunosuppressive "cold" tumor environment into an "active" one, enhancing the efficacy of other immunotherapies like PD-1/PD-L1 inhibitors. The presence and activation of these cells serve as key indicators of a successful anti-tumor immune response and are being investigated in various solid tumors, including melanoma and lung cancer.

Other names

TGF-beta-specific CD4+ T cellTGF-beta-peptide-reactive CD4+ T lymphocyteTGF-beta-specific T-helper cellTransforming growth factor beta-specific CD4+ T cell

Vaccine-mediated induction and expansion of T cells that recognize and eliminate TGF-beta-expressing immunosuppressive cells.